| Popis: |
Ali Alavi Foumani,1 Mojtaba Mehrdad,1,2 Alireza Jafarinezhad,1 Khadijeh Nokani,3 Alireza Jafari11Inflammatory Lung Diseases Research Center, Department of Internal Medicine, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; 2Razi Clinical Research Development Center, Guilan University of Medical Sciences, Rasht, Iran; 3Student Research Committee, Department of Internal Medicine, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, IranAbstract: COPD is an irreversible chronic illness with airflow limitation. The aim of the current study was to assess the role of vitamin D3 on quality of life and pulmonary function in patients with COPD. A randomized, double-blinded clinical trial was conducted in 63 patients with COPD. Patients were placed into intervention and placebo groups. Each individual in the intervention group took 50,000 IU vitamin D3once a week for 8 weeks and then once a month for 4 months. There was no significant difference among FEV1, FEV1/FVC, and number of exacerbations in patients with COPD (P>0.05). In the intervention group, a significant difference was observed in quality of life at 2 months (P |
